The Pharmaceutical Market: Japan

Date: January 31, 2013
Pages: 99
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PAD3FF12CF6EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Japan
OVERVIEW OF THE PHARMACEUTICAL MARKET IN JAPAN

Japan's ageing and affluent population represents strong opportunities for foreign drugmakers. However, given its weak macroeconomic, there is a risk that the country will not be able to sustain its generous welfare for the people and will seek to save costs through the use of more generic drugs and price cuts. Nevertheless, the current profile broods well for generic drugmakers as well as companies focusing on eldercare and chronic disease management.

Headline Expenditure Projections

Pharmaceuticals: JPY10,157bn (US$127.4bn) in 2011 to JPY10,206bn (US$130.9bn) in 2012; +0.5% in local currency terms and +2.7% in US dollar terms. Our forecast is unchanged since Q312.

Healthcare: JPY47,810bn (US$599.60bn) in 2011 to JPY49,305bn (US$632bn) in 2012; +3.0% in local currency terms and +5.4% in US dollar terms. Our forecast has been revised upwards slightly from Q412 following reassessment of historic data.

Medical Devices: JPY2,220bn (US$27.8bn) in 2011 to JPY2,212bn (US$28.4n) in 2012; -0.5% in local currency terms and +1.9% in US dollar terms. Forecast slightly downgraded from Q412 due to reassessment of historic values.
Risk/Reward Rating: In Q113, Japan's score on BMI's Asia Pacific Pharmaceutical Risk/Reward Ratings maintains at 77.0 and continues to enjoy its status as the most attractive pharmaceutical market in the region. The country scores highly for all indicators in the proprietary model, including an ageing population, large pharmaceutical market, lack of corruption and extensive bureaucracy and will continue to be targeted by multinational drugmakers both innovative and generics.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Japan Pharmaceuticals And Healthcare Industry SWOT
    Japan Political SWOT
    Japan Economic SWOT
    Japan Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: Asia Pacific Pharmaceutical & Healthcare Risk/Reward Ratings, Q113
    Rewards
    Risks

MARKET SUMMARY

REGULATORY REGIME

    Table: NCEs Approved by Origin, 2000-2010
    Table: Timeline Of NHI Drug List Price Cuts In Japan, 1992-2010

INDUSTRY TRENDS AND DEVELOPMENTS

    Epidemiology
    Non-Communicable Diseases
    Communicable Diseases
    Mental Health
    Healthcare Sector
    Clinical Trials

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Pharmaceutical Sales, Historical Data and Forecasts
    Key Growth Factors – Industry
    Table: Healthcare Expenditure Trends, Historical Data and Forecasts
    Table: Government Healthcare Expenditure Trends, Historical Data and Forecasts
    Table: Private Healthcare Expenditure Trends, Historical Data and Forecasts
    Key Growth Factors – Macroeconomic
    Prescription Drug Market Forecast
    Table: Prescription Drug Market Indicators, Historical Data and Forecasts
    Patented Drug Market Forecast
    Table: Patented Drug Market Indicators, Historical Data and Forecasts
    Generic Drug Market Forecast
    Table: Generics Drug Market Indicators, Historical Data and Forecasts
    OTC Medicine Market Forecast
    Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
    Medical Device Market Forecast
    Table: Medical Device Market Indicators, Historical Data and Forecasts
    Pharmaceutical Trade Forecast
    Table: Pharmaceutical Trade Data And Forecasts (US$mn)
    Table: Pharmaceutical Trade Data And Forecasts (JPYmn)
    Other Healthcare Data
      Key Risks To BMI's Forecast Scenario

COMPETITIVE LANDSCAPE

      Pharmaceutical Industry
      Top 15 Pharmaceutical Companies According To Market Capitalisation On The Tokyo Stock Exchange
      Foreign Generic Drug Sector
      Pharmaceutical Wholesale
      Trade Association
      Pharmaceutical Retail
      Trade Association
      Selected Pharmacy Chains
      Recent Company Developments

COMPANY PROFILES

  Local Companies
      Takeda Pharmaceutical Company
      Astellas
      Eisai
      Daiichi Sankyo
      Mitsubishi Tanabe
      Sawai Pharmaceutical
  Multinational Companies
      Pfizer
      Sanofi
      Merck & Co (Banyu)
      Novartis
      GlaxoSmithKline
      AstraZeneca

DEMOGRAPHIC OUTLOOK

      Table: Population By Age Group, 1990-2020 ('000)
      Table: Population By Age Group, 1990-2020 (% of total)
      Table: Key Population Ratios, 1990-2020
      Table: Rural/Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

      How We Generate Our Pharmaceutical Industry Forecasts
      Risk/Reward Ratings Methodology
      Ratings Overview
      Table: Pharmaceutical Business Environment Indicators
      Weighting
      Table: Weighting Of Components
      Sources
Skip to top


The True State of the Pharmaceutical Industry US$ 695.00 Dec, 2008 · 224 pages
The Pharmaceutical Market: USA US$ 1,295.00 Jan, 2013 · 107 pages
The Pharmaceutical Market: China US$ 1,295.00 Jan, 2013 · 118 pages

Ask Your Question

The Pharmaceutical Market: Japan
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: